7 March 2025
Transaction by Person
Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that,
on 6 March 2025, an award of the Company's ordinary shares of $0.25
each (Ordinary Shares) vested to Pascal Soriot, Executive Director
and Chief Executive Officer, under the terms of the AstraZeneca
Performance Share Plan (AZPSP).
The AZPSP award was granted on 6 March 2020 and
was subject to a three-year performance period. On the third
anniversary of grant the award was placed in a two-year holding
period. The award vested at the end of that holding period.
Application of the performance measures specified at the time of
grant resulted in 97% of the AZPSP award vesting and the remaining
unvested part lapsing.
Following the reinvestment of dividends accrued
during performance and holding periods of the AZPSP award, and the
withholding of shares to satisfy certain tax obligations arising on
vesting, Mr Soriot's beneficial interests in Ordinary Shares
changed as detailed in the table below:
|
PDMR
|
Ordinary Shares acquired under the
AZPSP
|
|
Pascal Soriot
|
89,962
|
For tax purposes, the fair market value of an
Ordinary Share at vest of the AZPSP award was 12,062 pence, being
the closing price on the last trading day preceding the
vesting.
Further details are set out in the attached
notification, made in accordance with the requirements of the EU
Market Abuse Regulation (as it forms part of UK law pursuant to the
European Union (Withdrawal) Act 2018.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Pascal Soriot
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.25 each in
AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Acquisition of ordinary shares
pursuant to a vesting under the AstraZeneca Performance Share Plan,
for nil consideration.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
0
|
89,962
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single
transaction
|
|
e)
|
Date of the transaction
|
6 March 2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is
a global, science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
